India should remain on 301 ‘Priority Watch List’, says PhRMA

India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Indian committee advocates compulsory licensing and price caps

28 January 2019 Indian pharmaceutical companies should be encouraged to grant compulsory licences and prices of some patented medicines should be capped, an Indian government panel has said.

Asia

Indian drug makers end generic bids

18 April 2016 Indian-based drugs companies BDR Pharmaceutical and Lee Pharmaceutical have reportedly abandoned their attempt to produce generic versions of two drugs developed by AstraZeneca and Bristol-Myers Squibb.

More on this story

Asia

Indian committee advocates compulsory licensing and price caps

28 January 2019 Indian pharmaceutical companies should be encouraged to grant compulsory licences and prices of some patented medicines should be capped, an Indian government panel has said.

Asia

Indian drug makers end generic bids

More on this story

Asia

Indian committee advocates compulsory licensing and price caps

28 January 2019 Indian pharmaceutical companies should be encouraged to grant compulsory licences and prices of some patented medicines should be capped, an Indian government panel has said.

Asia

Indian drug makers end generic bids